Glivec® Receives Additional EU Approvals For Use In Treating A Rapidly Progressive Form Of Leukemia And A Hard-to-treat Solid Cancer Tumor

... Novartis has received additional European Union approvals for Glivec® (imatinib) to help patients with a rapidly progressive form of leukemia as well as a hard-to-treat solid cancer tumor. Both are rare and potentially life-threatening diseases with few, if any, approved treatments that have resulted in poor long-term outcomes. [click link for full article] ...